MedTrace Logo

Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors

NCT03360890 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-03-13

No results posted yet for this study

Summary

Phase II, 2-cohort, single arm trial treated with the combination of the following two agents:

1. Pembrolizumab (MK3475) 200mg, every three weeks, iv
2. Docetaxel 75mg/m2, every three weeks, iv

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab will be administered via IV at 200mg every three weeks. Patients will receive pembrolizumab for about 2 years.

DRUG

Docetaxel

Docetaxel will be administered via IV at 75mg/m2 every three weeks for 3 to 6 cycles.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Alexander Pearson · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-26
Primary Completion
2025-12-05
Completion
2032-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03360890 on ClinicalTrials.gov